Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6L
+2.87%+4.57%+70.82%+119.22% 5.52TCr
+4.00%+7.14%+63.67%+68.77% 4.58TCr
+0.12%+0.62%-11.31%-14.86% 2.3TCr
+2.93%+1.53%-6.14%+386.48% 2.08TCr
-0.26%-1.09%+27.55%-18.57% 1.63TCr
+1.16%+3.86%+22.36%-36.42% 1.54TCr
-1.21%-2.92%+18.64%+158.83% 1.3TCr
+3.30%+15.38%+133.24%+273.89% 1.24TCr
-5.63%-5.49%+21.79% - 1.24TCr
Average +0.71%+3.15%+37.85%+117.17% 2.38TCr
Weighted average by Cap. +1.73%+2.66%+43.87%+109.12%
Logo Protalex, Inc.
Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!